Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Steven A. Narod; Marie Pierre Dubé; Jan Klijn; Jan Lubinski; Henry T. Lynch; Parviz Ghadirian; Daine Provencher; Ketil Heimdal; Pal Moller; Mark Robson; Kenneth Offit; Claudine Isaacs; Barbara Weber; Eitan Friedman; Ruth Gershoni-Baruch; Gad Rennert; Barbara Pasini; Theresa Wagner; Mary Daly; Judy E. Garber; Susan L. Neuhausen; Peter Ainsworth; Hakan Olsson; Gareth Evans; Michael Osborne; Fergus Couch; William D. Foulkes; Ellen Warner; Charmaine Kim-Sing; Olufunmilayo Olopade; Nadine Tung; Howard M. Saal; Jeffrey Weitzel; Sofia Merajver; Marion Gauthier-Villars; Helena Jernstrom; Ping Sun; Jean Sebastien Brunet

doi:10.1093/jnci/94.23.1773

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Steven A. Narod, Marie Pierre Dubé, Jan Klijn, Jan Lubinski, Henry T. Lynch, Parviz Ghadirian, Daine Provencher, Ketil Heimdal, Pal Moller, Mark Robson, Kenneth Offit, Claudine Isaacs, Barbara Weber, Eitan Friedman, Ruth Gershoni-Baruch, Gad Rennert, Barbara Pasini, Theresa Wagner, Mary Daly, Judy E. GarberSusan L. Neuhausen, Peter Ainsworth, Hakan Olsson, Gareth Evans, Michael Osborne, Fergus Couch, William D. Foulkes, Ellen Warner, Charmaine Kim-Sing, Olufunmilayo Olopade, Nadine Tung, Howard M. Saal, Jeffrey Weitzel, Sofia Merajver, Marion Gauthier-Villars, Helena Jernstrom, Ping Sun, Jean Sebastien Brunet

Research output: Contribution to journal › Article › peer-review

338 Scopus citations

Abstract

Background: Oral contraceptive use has been associated with an increase in the risk of breast cancer in young women. We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2. Methods: We performed a matched case-control study on 1311 pairs of women with known deleterious BRCA1 and/or BRCA2 mutations recruited from 52 centers in 11 countries. Women who had been diagnosed with breast cancer were matched to control subjects by year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of ovarian cancer. All study subjects completed a questionnaire about oral contraceptive use. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived by conditional logistic regression. All statistical tests were two-sided. Results: Among BRCA2 mutation carriers, ever use of oral contraceptives was not associated with an increased risk of breast cancer (OR = 0.94, 95% CI = 0.72 to 1.24). For BRCA1 mutation carriers, ever use of oral contraceptives was associated with a modestly increased risk of breast cancer (OR = 1.20, 95 % CI = 1.02 to 1.40). However, compared with BRCA1 mutation carriers who never used oral contraceptives, those who used oral contraceptives for at least 5 years had an increased risk of breast cancer (OR = 1.33, 95% CI = 1.11 to 1.60), as did those who used oral contraceptives before age 30 (OR = 1.29, 95% CI = 1.09 to 1.52), those who were diagnosed with breast cancer before age 40 (OR = 1.38, 95% CI = 1.11 to 1.72), and those who first used oral contraceptives before 1975 (OR = 1.42, 95 % CI = 1. 17 to 1.75). Conclusions: Among BRCA1 mutation carriers, women who first used oral contraceptives before 1975, who used them before age 30, or who used them for 5 or more years may have an increased risk of early-onset breast cancer. Oral contraceptives do not appear to be associated with risk of breast cancer in BRCA2 carriers, but data for BRCA2 carriers are limited.

Original language	English
Pages (from-to)	1773-1779
Number of pages	7
Journal	Journal of the National Cancer Institute
Volume	94
Issue number	23
DOIs	https://doi.org/10.1093/jnci/94.23.1773
State	Published - Dec 4 2002

Keywords

Adolescent
Adult
Age of Onset
Breast Neoplasms/chemically induced
Case-Control Studies
Contraceptives, Oral, Hormonal/administration & dosage
Drug Administration Schedule
Female
Genes, BRCA1
Genes, BRCA2
Heterozygote
Humans
Matched-Pair Analysis
Middle Aged
Mutation
Odds Ratio
Ovarian Neoplasms/complications
Risk Assessment
Risk Factors
Time Factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/94.23.1773

Cite this

Narod, S. A., Dubé, M. P., Klijn, J., Lubinski, J., Lynch, H. T., Ghadirian, P., Provencher, D., Heimdal, K., Moller, P., Robson, M., Offit, K., Isaacs, C., Weber, B., Friedman, E., Gershoni-Baruch, R., Rennert, G., Pasini, B., Wagner, T., Daly, M., ... Brunet, J. S. (2002). Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute, 94(23), 1773-1779. https://doi.org/10.1093/jnci/94.23.1773

@article{59982e4df91f4126b6a3578d1be2365d,

title = "Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers",

abstract = "Background: Oral contraceptive use has been associated with an increase in the risk of breast cancer in young women. We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2. Methods: We performed a matched case-control study on 1311 pairs of women with known deleterious BRCA1 and/or BRCA2 mutations recruited from 52 centers in 11 countries. Women who had been diagnosed with breast cancer were matched to control subjects by year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of ovarian cancer. All study subjects completed a questionnaire about oral contraceptive use. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived by conditional logistic regression. All statistical tests were two-sided. Results: Among BRCA2 mutation carriers, ever use of oral contraceptives was not associated with an increased risk of breast cancer (OR = 0.94, 95% CI = 0.72 to 1.24). For BRCA1 mutation carriers, ever use of oral contraceptives was associated with a modestly increased risk of breast cancer (OR = 1.20, 95 % CI = 1.02 to 1.40). However, compared with BRCA1 mutation carriers who never used oral contraceptives, those who used oral contraceptives for at least 5 years had an increased risk of breast cancer (OR = 1.33, 95% CI = 1.11 to 1.60), as did those who used oral contraceptives before age 30 (OR = 1.29, 95% CI = 1.09 to 1.52), those who were diagnosed with breast cancer before age 40 (OR = 1.38, 95% CI = 1.11 to 1.72), and those who first used oral contraceptives before 1975 (OR = 1.42, 95 % CI = 1. 17 to 1.75). Conclusions: Among BRCA1 mutation carriers, women who first used oral contraceptives before 1975, who used them before age 30, or who used them for 5 or more years may have an increased risk of early-onset breast cancer. Oral contraceptives do not appear to be associated with risk of breast cancer in BRCA2 carriers, but data for BRCA2 carriers are limited.",

keywords = "Adolescent, Adult, Age of Onset, Breast Neoplasms/chemically induced, Case-Control Studies, Contraceptives, Oral, Hormonal/administration & dosage, Drug Administration Schedule, Female, Genes, BRCA1, Genes, BRCA2, Heterozygote, Humans, Matched-Pair Analysis, Middle Aged, Mutation, Odds Ratio, Ovarian Neoplasms/complications, Risk Assessment, Risk Factors, Time Factors",

author = "Narod, {Steven A.} and Dub{\'e}, {Marie Pierre} and Jan Klijn and Jan Lubinski and Lynch, {Henry T.} and Parviz Ghadirian and Daine Provencher and Ketil Heimdal and Pal Moller and Mark Robson and Kenneth Offit and Claudine Isaacs and Barbara Weber and Eitan Friedman and Ruth Gershoni-Baruch and Gad Rennert and Barbara Pasini and Theresa Wagner and Mary Daly and Garber, {Judy E.} and Neuhausen, {Susan L.} and Peter Ainsworth and Hakan Olsson and Gareth Evans and Michael Osborne and Fergus Couch and Foulkes, {William D.} and Ellen Warner and Charmaine Kim-Sing and Olufunmilayo Olopade and Nadine Tung and Saal, {Howard M.} and Jeffrey Weitzel and Sofia Merajver and Marion Gauthier-Villars and Helena Jernstrom and Ping Sun and Brunet, {Jean Sebastien}",

year = "2002",

month = dec,

day = "4",

doi = "10.1093/jnci/94.23.1773",

language = "English",

volume = "94",

pages = "1773--1779",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "23",

}

Narod, SA, Dubé, MP, Klijn, J, Lubinski, J, Lynch, HT, Ghadirian, P, Provencher, D, Heimdal, K, Moller, P, Robson, M, Offit, K, Isaacs, C, Weber, B, Friedman, E, Gershoni-Baruch, R, Rennert, G, Pasini, B, Wagner, T, Daly, M, Garber, JE, Neuhausen, SL, Ainsworth, P, Olsson, H, Evans, G, Osborne, M, Couch, F, Foulkes, WD, Warner, E, Kim-Sing, C, Olopade, O, Tung, N, Saal, HM, Weitzel, J, Merajver, S, Gauthier-Villars, M, Jernstrom, H, Sun, P & Brunet, JS 2002, 'Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers', Journal of the National Cancer Institute, vol. 94, no. 23, pp. 1773-1779. https://doi.org/10.1093/jnci/94.23.1773

TY - JOUR

T1 - Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

AU - Narod, Steven A.

AU - Dubé, Marie Pierre

AU - Klijn, Jan

AU - Lubinski, Jan

AU - Lynch, Henry T.

AU - Ghadirian, Parviz

AU - Provencher, Daine

AU - Heimdal, Ketil

AU - Moller, Pal

AU - Robson, Mark

AU - Offit, Kenneth

AU - Isaacs, Claudine

AU - Weber, Barbara

AU - Friedman, Eitan

AU - Gershoni-Baruch, Ruth

AU - Rennert, Gad

AU - Pasini, Barbara

AU - Wagner, Theresa

AU - Daly, Mary

AU - Garber, Judy E.

AU - Neuhausen, Susan L.

AU - Ainsworth, Peter

AU - Olsson, Hakan

AU - Evans, Gareth

AU - Osborne, Michael

AU - Couch, Fergus

AU - Foulkes, William D.

AU - Warner, Ellen

AU - Kim-Sing, Charmaine

AU - Olopade, Olufunmilayo

AU - Tung, Nadine

AU - Saal, Howard M.

AU - Weitzel, Jeffrey

AU - Merajver, Sofia

AU - Gauthier-Villars, Marion

AU - Jernstrom, Helena

AU - Sun, Ping

AU - Brunet, Jean Sebastien

PY - 2002/12/4

Y1 - 2002/12/4

N2 - Background: Oral contraceptive use has been associated with an increase in the risk of breast cancer in young women. We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2. Methods: We performed a matched case-control study on 1311 pairs of women with known deleterious BRCA1 and/or BRCA2 mutations recruited from 52 centers in 11 countries. Women who had been diagnosed with breast cancer were matched to control subjects by year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of ovarian cancer. All study subjects completed a questionnaire about oral contraceptive use. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived by conditional logistic regression. All statistical tests were two-sided. Results: Among BRCA2 mutation carriers, ever use of oral contraceptives was not associated with an increased risk of breast cancer (OR = 0.94, 95% CI = 0.72 to 1.24). For BRCA1 mutation carriers, ever use of oral contraceptives was associated with a modestly increased risk of breast cancer (OR = 1.20, 95 % CI = 1.02 to 1.40). However, compared with BRCA1 mutation carriers who never used oral contraceptives, those who used oral contraceptives for at least 5 years had an increased risk of breast cancer (OR = 1.33, 95% CI = 1.11 to 1.60), as did those who used oral contraceptives before age 30 (OR = 1.29, 95% CI = 1.09 to 1.52), those who were diagnosed with breast cancer before age 40 (OR = 1.38, 95% CI = 1.11 to 1.72), and those who first used oral contraceptives before 1975 (OR = 1.42, 95 % CI = 1. 17 to 1.75). Conclusions: Among BRCA1 mutation carriers, women who first used oral contraceptives before 1975, who used them before age 30, or who used them for 5 or more years may have an increased risk of early-onset breast cancer. Oral contraceptives do not appear to be associated with risk of breast cancer in BRCA2 carriers, but data for BRCA2 carriers are limited.

AB - Background: Oral contraceptive use has been associated with an increase in the risk of breast cancer in young women. We examined whether this association is seen in women at high risk of breast cancer because they carry a mutation in one of two breast cancer susceptibility genes, BRCA1 and BRCA2. Methods: We performed a matched case-control study on 1311 pairs of women with known deleterious BRCA1 and/or BRCA2 mutations recruited from 52 centers in 11 countries. Women who had been diagnosed with breast cancer were matched to control subjects by year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of ovarian cancer. All study subjects completed a questionnaire about oral contraceptive use. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived by conditional logistic regression. All statistical tests were two-sided. Results: Among BRCA2 mutation carriers, ever use of oral contraceptives was not associated with an increased risk of breast cancer (OR = 0.94, 95% CI = 0.72 to 1.24). For BRCA1 mutation carriers, ever use of oral contraceptives was associated with a modestly increased risk of breast cancer (OR = 1.20, 95 % CI = 1.02 to 1.40). However, compared with BRCA1 mutation carriers who never used oral contraceptives, those who used oral contraceptives for at least 5 years had an increased risk of breast cancer (OR = 1.33, 95% CI = 1.11 to 1.60), as did those who used oral contraceptives before age 30 (OR = 1.29, 95% CI = 1.09 to 1.52), those who were diagnosed with breast cancer before age 40 (OR = 1.38, 95% CI = 1.11 to 1.72), and those who first used oral contraceptives before 1975 (OR = 1.42, 95 % CI = 1. 17 to 1.75). Conclusions: Among BRCA1 mutation carriers, women who first used oral contraceptives before 1975, who used them before age 30, or who used them for 5 or more years may have an increased risk of early-onset breast cancer. Oral contraceptives do not appear to be associated with risk of breast cancer in BRCA2 carriers, but data for BRCA2 carriers are limited.

KW - Adolescent

KW - Adult

KW - Age of Onset

KW - Breast Neoplasms/chemically induced

KW - Case-Control Studies

KW - Contraceptives, Oral, Hormonal/administration & dosage

KW - Drug Administration Schedule

KW - Female

KW - Genes, BRCA1

KW - Genes, BRCA2

KW - Heterozygote

KW - Humans

KW - Matched-Pair Analysis

KW - Middle Aged

KW - Mutation

KW - Odds Ratio

KW - Ovarian Neoplasms/complications

KW - Risk Assessment

KW - Risk Factors

KW - Time Factors

UR - http://www.scopus.com/inward/record.url?scp=0037021659&partnerID=8YFLogxK

U2 - 10.1093/jnci/94.23.1773

DO - 10.1093/jnci/94.23.1773

M3 - Article

C2 - 12464649

AN - SCOPUS:0037021659

SN - 0027-8874

VL - 94

SP - 1773

EP - 1779

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 23

ER -

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this